Reta Weight Loss Is Real. The Product You’d Buy Isn’t Approved.
Retatrutide has now finished four Phase 3 trials, all reporting positive, and Eli Lilly says it plans to file for FDA approval in the first quarter of 2027. None of that makes the vials sold online today legal or verified: the FDA has told compounders directly that retatrutide cannot legally be compounded.
Reviewed by the PepGuard team · Last reviewed Jul 28, 2026
Investigational triple agonist targeting GIP, GLP-1, and glucagon receptors · also called LY3437943, triple GIP, GLP-1, and glucagon receptor agonist
Photo: Haley Lawrence / UnsplashFive positive Phase 3 trials. Zero approved vials.
Eli Lilly’s TRIUMPH program set out in 2023 to answer whether retatrutide, a single molecule that activates the GIP, GLP-1, and glucagon receptors at once, actually works across the conditions obesity drives: weight itself, type 2 diabetes, cardiovascular risk, and joint pain. Four registrational Phase 3 trials, more than 5,800 participants, and every one of them has now completed and met its primary endpoint. In TRIUMPH-1, the largest of the four, the group on the highest dose lost an average of 28.3% of body weight, 70.3 lbs, over 80 weeks, against 2.2% (5.5 lbs) on placebo.
That’s the strongest case retatrutide has ever had. It’s also, as of today, still not an FDA-approved drug. Lilly has said it plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027 — a planned filing, not a submission, and a submission is not a review, and a review is not an approval. Below is what the trials actually tested, followed by what’s actually legal to buy today, which is a much shorter list.
What each TRIUMPH trial actually found.
TRIUMPH-1 (2,339 adults with obesity/overweight, 80 weeks): the 12 mg group reached -28.3% body weight (70.3 lbs) versus -2.2% (5.5 lbs) on placebo; 45.3% of that group lost 30% or more. A 104-week extension in participants with a starting BMI of 35 or higher reached -30.3% (85.0 lbs).
TRIUMPH-1’s nested basket trials (knee osteoarthritis and moderate-to-severe obstructive sleep apnea, run inside the same trial population): pain scores on the WOMAC scale fell by up to 4.3 points, 73.1%, and the apnea-hypopnea index fell by up to 36.1 events per hour, 60.6%. Both baskets met their primary endpoints.
TRIUMPH-2 (1,152 adults with type 2 diabetes and obesity, 80 weeks): -20.8% weight loss (49.6 lbs) at 12 mg, alongside up to a 1.6% average A1C reduction.
TRIUMPH-3 (1,949 adults with obesity and established cardiovascular disease, 80 weeks): -22.6% weight loss (55.8 lbs) at 12 mg. This is also the release where Lilly stated its plan to file a BLA with the FDA in Q1 2027.
TRIUMPH-4 (445 adults with knee osteoarthritis, 84.0% with a starting BMI of 35 or higher, 68 weeks): -20.0% to -23.7% weight loss (50.5-60.0 lbs) and a WOMAC pain-score reduction of 62.6%-67.2%, on the more conservative treatment-regimen estimand.
Every number above is Lilly’s own company-reported topline result. None of it has been through peer review yet — no TRIUMPH results paper has published as of this writing.
What the Phase 3 trials actually dosed.
| What's cited | Range |
|---|---|
| TRIUMPH Phase 3 program (all 4 trials) | 4 mg, 9 mg, or 12 mg, subcutaneous, once weekly |
| TRIUMPH-1 (obesity/overweight, n=2,339) | 4/9/12 mg weekly vs. placebo, 80 weeks + 104-week extension |
| TRIUMPH-4 (knee osteoarthritis, n=445) | 9 mg or 12 mg weekly vs. placebo, 68 weeks |
| Phase 2 dose-finding (2023, historical) | 1, 4, 8, or 12 mg weekly, 48 weeks |
| Dose for retatrutide sold outside a Lilly trial | Not established — no approved product or verified formulation exists |
The dose levels below are the arms Lilly tested in its registrational Phase 3 program, under medical supervision, not a treatment protocol. TRIUMPH-4's more conservative treatment-regimen results also found a real tolerability cost at higher doses: 12.2% of the 9 mg group and 18.2% of the 12 mg group discontinued the trial due to an adverse event, versus 4.0% on placebo. None of this describes a self-administered vial bought outside a Lilly trial.
What TRIUMPH’s own safety data shows.
| Signal | Frequency | Context |
|---|---|---|
| Gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) | commonly reported | Consistent across the Phase 2 trial and the TRIUMPH Phase 3 program; described as dose-related and mostly mild to moderate. |
| Increased heart rate | occasionally reported | The Phase 2 trial reported dose-dependent increases peaking around 24 weeks; not yet independently reported for TRIUMPH in a peer-reviewed source. |
| Discontinuation due to adverse events (TRIUMPH-4) | occasionally reported | 12.2% of the 9 mg group and 18.2% of the 12 mg group stopped the trial due to an adverse event, versus 4.0% on placebo, per Lilly's company-reported TRIUMPH-4 results. |
| Long-term and real-world safety | unknown / not studied | No trial in the program has followed participants beyond roughly two years, and there is no post-marketing data because no product has been approved. |
There is no legal way to buy retatrutide today.
The FDA has said this directly: “Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.” There is no pharmacy, compounder, or telehealth channel that can legally sell it.
One legitimate access route does exist: Lilly’s pre-approval expanded access program (ClinicalTrials.gov NCT07629401). It’s for adults with a BMI of 35 or higher who have already tried the highest available dose of standard weight-management therapy, have two or more serious obesity-related complications, and can’t join an ongoing retatrutide trial. Access is physician-initiated only, through Lilly’s Answers Center at 1-800-545-5979 — a patient or caregiver is directed to their treating physician, not to Lilly directly. That is categorically different from ordering “retatrutide” from a research-chemical vendor or a telehealth site marketing it directly to consumers, which is exactly the activity the FDA has been sending warning letters over.
There is no legitimate price to quote.
No primary source, not the FDA, not Lilly, not a clinical trial registry, publishes a price for retatrutide, because no approved retatrutide product exists to price. Any dollar figure attached to “retatrutide” online describes material the FDA has already said cannot legally be compounded or sold. PepGuard isn’t going to repeat a vendor’s number for a product that doesn’t legally exist yet.
FDA sent at least six warning letters in a single day over this exact drug.
Retatrutide has never been approved by the FDA for any use. Eli Lilly has completed four Phase 3 TRIUMPH trials and has stated it plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027 — a planned filing is not a submission, a submission is not a review, and a review is not an approval. In the meantime, the FDA has been explicit that retatrutide cannot legally be compounded: "Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition." The agency has separately warned telehealth companies, active-pharmaceutical-ingredient distributors, and outsourcing facilities involved in selling or repackaging it. On September 9, 2025 alone, it sent at least six warning letters to different sellers — including GLP-1 Solution, Amazing Meds, GenLabMeds, MedClub by Dr. Jenn, ASN-LABS, and EA Works LLC dba Trust Labs — each citing the identical reason: compounded retatrutide fails both the 503A and 503B exemptions because it does not appear on either bulk-drug-substance list and is not a component of any FDA-approved drug.
Retatrutide is not a cagrilintide stack
Retatrutide is a triple agonist, while cagrilintide is an amylin analogue. The published trials evaluate them as separate investigational products, not as a combined self-treatment.
Every claim above, traced back.
Four Phase 3 press releases, the TRIUMPH design paper, two ClinicalTrials.gov registrations, and two FDA regulatory pages. Click through and check them yourself.
Retatrutide questions, answered.
No. As of today, retatrutide has no FDA approval for any use. Eli Lilly has completed all four Phase 3 TRIUMPH trials and has stated it plans to submit a Biologics License Application (BLA) to the FDA in the first quarter of 2027. A planned filing is not a submission, a submission is not a review, and a review is not an approval — each of those steps still has to happen.
There is no legal retail or prescription channel for retatrutide today, because no version of it is FDA-approved. The one legitimate access route is Eli Lilly's pre-approval expanded access program (ClinicalTrials.gov NCT07629401), for adults with a BMI of 35 or higher who have already tried the highest available dose of standard weight-management therapy, have two or more serious obesity-related complications, and can't join an ongoing retatrutide trial. It's physician-initiated only, through Lilly's Answers Center at 1-800-545-5979 — patients and caregivers are directed to go through their treating physician, not to contact Lilly directly. That's categorically different from buying "retatrutide" from a telehealth site or research-chemical vendor.
There is no legitimate price to quote, because there is no FDA-approved retatrutide product on the market to price. The FDA has stated plainly that retatrutide "cannot be used in compounding under federal law" and is "not a component of an FDA-approved drug." Any dollar figure attached to "retatrutide" online is for material sold outside that framework, and PepGuard won't publish a price for a product that doesn't legally exist yet.
All four TRIUMPH trials tested the same once-weekly subcutaneous doses against placebo: 4 mg, 9 mg, and 12 mg (TRIUMPH-4 tested only 9 mg and 12 mg). Those are supervised clinical-trial doses with medical monitoring, not a self-administration protocol.
Across four trials and more than 5,800 participants, every arm met its primary endpoint. In TRIUMPH-1 (n=2,339, 80 weeks), the 12 mg group lost an average of 28.3% of body weight (70.3 lbs) versus 2.2% (5.5 lbs) with placebo. TRIUMPH-2 (n=1,152, type 2 diabetes) reached 20.8% weight loss (49.6 lbs) at 12 mg plus up to a 1.6% average A1C reduction. TRIUMPH-3 (n=1,949, cardiovascular disease) reached 22.6% (55.8 lbs) at 12 mg. TRIUMPH-4 (n=445, knee osteoarthritis) reported 20.0%-23.7% weight loss and a WOMAC pain-score reduction of up to 67-76%. These are Lilly's own company-reported topline numbers; no peer-reviewed TRIUMPH results paper has published yet.
The most consistently reported side effects, across both the 2023 Phase 2 trial and the TRIUMPH Phase 3 program, are gastrointestinal: nausea, diarrhea, vomiting, and constipation, generally dose-related and mild to moderate. TRIUMPH-4 also reported a real tolerability cost at higher doses: 12.2% of the 9 mg group and 18.2% of the 12 mg group discontinued the trial due to an adverse event, compared with 4.0% on placebo. None of the TRIUMPH safety data has been independently peer-reviewed, and there's no long-term or real-world safety data because no product has ever been marketed.
Not verifiably. The weight-loss results above come from retatrutide manufactured and dosed inside an Eli Lilly clinical trial, under FDA oversight. A vial marketed online as "reta" or "retatrutide" has none of that: it isn't an approved product, the FDA says it cannot legally be compounded, and there's no regulatory mechanism confirming its identity, purity, or dose match what was studied.
Keep researching.
This is a preview of the Retatrutide report.
Create your account to check any peptide against the full research base.